Company intelligence / Profile preview

ProFACT Proteomics

Monmouth Junction, New Jersey, United Statesprofact.rutgers.edu ↗

Ownership: Private
Development stage: Commercial

Overview

ProFACT Proteomics provides proprietary functional proteomic platforms that enable reduction of protein complexity, creation of functional sub-proteomes, and enrichment/isolation of functionally active proteins. Their SeraFILE™ platform is used for biomarker and drug target discovery—principally in cancer—and has been referenced in over 100 technical journals. The company’s technologies are used by biopharma clients for early-stage research, assay development, and personalized medicine applications.

Therapeutic areas: OtherOncology
Modalities: N/A – enabling tech
Industry: Drug Discovery Services

Partnerships

Biotech Support Group LLC

Beyond the preview

Go deeper on ProFACT Proteomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProFACT Proteomics.

Explore the full profile